Mithramycin A
CAS No. 18378-89-7
Mithramycin A ( Plicamycin;PA 144;NSC 24559 )
Catalog No. M12838 CAS No. 18378-89-7
A tricyclic pentaglycosidic, antineoplastic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 385 | In Stock |
|
10MG | 575 | In Stock |
|
25MG | 888 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMithramycin A
-
NoteResearch use only, not for human use.
-
Brief DescriptionA tricyclic pentaglycosidic, antineoplastic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA.
-
DescriptionA tricyclic pentaglycosidic, antineoplastic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA; binds to the minor groove of DNA at GC-rich sites, induces cancer cell apoptosis and metastasis.
-
SynonymsPlicamycin;PA 144;NSC 24559
-
PathwayCell Cycle/DNA Damage
-
TargetDNA/RNA Synthesis
-
RecptorDNA/RNA Synthesis
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number18378-89-7
-
Formula Weight1085.00
-
Molecular FormulaC52H76O24
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@@H](O[C@H]4C[C@](C)(O)[C@H](O)[C@@H](C)O4)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H]([C@H](OC)C([C@@H](O)[C@H](O)C)=O)CC5=C1C(O)=C6C(O)=C(C)C(O[C@H]7C[C@@H](O[C@H]8C[C@@H](O)[C@H](O)[C@@H](C)O8)[C@H](O)[C@@H](C)O7)=CC6=C5
-
Chemical Name(2S,3S)-3-((1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl)-2-(((2S,4R,5R,6R)-4-(((2S,4R,5S,6R)-4-(((2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Boro A, et al. Int J Cancer. 2012 Nov 1;131(9):2153-64.
2. Lee TJ, et al. Mol Cancer Ther. 2006 Nov;5(11):2737-46.
3. Majee S, et al. Biochem Pharmacol. 1999 May 1;57(9):981-7.
2. Lee TJ, et al. Mol Cancer Ther. 2006 Nov;5(11):2737-46.
3. Majee S, et al. Biochem Pharmacol. 1999 May 1;57(9):981-7.
molnova catalog
related products
-
CX-5461
CX-5461 is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I.
-
T863
T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.
-
UM-164
UM-164 is a highly potent inhibitor ofc-Srcwith aKdof 2.7 nM. UM-164 also potently inhibitsp38αandp38β.